cas 4857-04-9|| where to buy 2-(chloromethyl)-1H-benzo[d]imidazole

Nom du produit:2-(chloromethyl)-1H-benzo[d]imidazole

IUPAC Name:2-(chloromethyl)-1H-1,3-benzodiazole

Unité d'emballage	Stock disponible	Prix($)
CM100059-25g	in stock	șǕ
CM100059-100g	in stock	ȀƏș

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 4857-04-9 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:4857-04-9; Formule moléculaire:C8H7ClN2; Point de fusion:-; Code SMILES:ClCC1=NC2=CC=CC=C2N1; Densité:1.356g/cm3

: Numéro de catalogue:CM100059; Poids moléculaire:166.61; Point d'ébullition:371°C at 760 mmHg; N° Mdl:MFCD00005602; Stockage:Store at 2-8°C.

: Benzimidazoles; Benzimidazole is a benzo derivative of imidazole. It is a kind of bicyclic aromatic organic compounds, which is formed by fusing a six-membered benzene ring and five-membered imidazole at positions 4 and 5 of imidazole ring. It is an important pharmacophore of many biologically active heterocyclic compounds with various pharmacological activities. Benzimidazoles and their derivatives have developed into dynamic heterocyclic systems due to their potency in a variety of biologically active compounds such as anticancer, bactericidal and antiviral drugs. Benzimidazoles are a class of therapeutic motifs with broad relevance in medicinal chemistry.

: Benzo Heterocycles; Benzoheterocycles are heterocycles which are fused with a benzene ring. Coumarone, thianaphthene, benzopyridine, isoquinoline, and dibenzopyridine all belong to this class of compounds.

: Mavorixafor; X4 Pharmaceuticals’ lead product candidate, Mavorixafor (X4P-001) has reached a significant milestone with the submission of a New Drug Application (NDA) to the U.S. FDA for the treatment of WHIM Syndrome on September 5. This marks an important step forward in the regulatory approval process for Mavorixafor and highlights its potential as a promising therapy for patients with WHIM Syndrome.
WHIM syndrome was named after four symptoms: Warts, Hypogammaglobulinemia, Infections, Myelokathexis. WHIM syndrome is a rare and difficult-to-diagnose primary immunodeficiency in which the body’s immune system does not function properly and has trouble fighting infections, especially respiratory, ear, and skin infections.
Mavorixafor is an investigational small-molecule CXCR4 antagonist. It allosterically blocks the overstimulation of the CXCL12/CXCR4 pathway, having the potential to improve immune cell trafficking and immunosurveillance. Mavorixafor was designated orphan drug status by both the U.S. and the EU, and previously granted Fast Track Designation and Breakthrough Therapy Designation by the FDA.